Form 4: Berkshire Hathaway Plans DaVita Share Sale

Berkshire Hathaway Inc. reported a planned sale of 401,514 DaVita Inc. common shares at $135.3558 per share, executed under a Rule 10b5-1 plan.

Summary

• Berkshire Hathaway Inc. plans to sell 401,514 shares of DaVita Inc. common stock.
• The transaction is scheduled for October 27, 2025, at a price of $135.3558 per share.
• This sale is being conducted pursuant to a Rule 10b5-1 trading plan, indicating a pre-scheduled disposition.
• Following this transaction, Berkshire Hathaway Inc. will beneficially own 31,759,065 shares of DaVita Inc. common stock indirectly.
• The total estimated value of the shares to be sold is approximately $54.34 million.
• Indirect beneficial ownership includes 15,126,977 shares held by Government Employees Insurance Company (GEICO) and 16,632,088 shares held by Berkshire's subsidiary pension plans (BNSF Master Retirement Trust and Berkshire Hathaway Inc. Consolidated Pension Plan).

Sentiment

Score: 4

Explanation: A planned sale by a significant institutional investor, while not necessarily a strong negative signal due to the 10b5-1 plan, still represents a reduction in their stake and could be perceived with slight caution by the market.

Positives

• The transaction is executed under a Rule 10b5-1 plan, indicating a pre-scheduled, orderly disposition of shares rather than an immediate reaction to new negative information.

Negatives

• A reduction in the stake held by a prominent institutional investor like Berkshire Hathaway Inc. could be perceived negatively by the market, potentially signaling reduced long-term conviction.

Risks

• Potential negative market perception due to a significant institutional investor reducing its stake, which could lead to downward pressure on DaVita Inc.'s share price.

Future Outlook

Berkshire Hathaway Inc. has scheduled the sale of 401,514 shares of DaVita Inc. common stock for October 27, 2025, under a Rule 10b5-1 trading plan. This indicates a pre-determined disposition of shares rather than a reaction to immediate market conditions.

Management Comments

• Warren E. Buffett signed the filing on behalf of himself and each other reporting person hereunder, disclaiming beneficial ownership of reported securities except to the extent of his pecuniary interest therein.

Industry Context

This transaction reflects a planned adjustment in a major institutional investor's portfolio rather than a direct commentary on the healthcare services industry or DaVita Inc.'s operational performance. Large-scale, pre-scheduled sales by significant shareholders are common for portfolio rebalancing or liquidity management.

Comparison to Industry Standards

• This Form 4 filing reports an insider transaction (a planned sale of shares) by a significant institutional investor, Berkshire Hathaway Inc., rather than operational or financial results of DaVita Inc. As such, direct comparisons to industry-standard operational or financial benchmarks for DaVita Inc. are not applicable in this context.
• The use of a Rule 10b5-1 plan for share disposition is a common practice among corporate insiders and large institutional investors to manage stock sales in compliance with insider trading regulations, providing an affirmative defense against claims of trading on material non-public information. This practice itself aligns with industry best practices for orderly share divestment.

Related Party Transactions

• Beneficial ownership includes shares held by Government Employees Insurance Company (GEICO), a subsidiary of Berkshire Hathaway Inc., and pension plans of Berkshire's subsidiaries (BNSF Master Retirement Trust and Berkshire Hathaway Inc. Consolidated Pension Plan).

Stakeholder Impact

• Shareholders may interpret the planned reduction in Berkshire Hathaway's stake as a potential signal of reduced long-term confidence, which could influence investor sentiment and share price.
• The orderly nature of the sale via a 10b5-1 plan may mitigate some negative impact compared to an unplanned, reactive sale.

Next Steps

• The scheduled transaction of 401,514 shares of DaVita Inc. common stock is set to occur on October 27, 2025.

Key Dates

Recommendation

The reported transaction is a pre-scheduled sale under a Rule 10b5-1 plan by a significant institutional investor. While it reduces Berkshire Hathaway's stake, it does not necessarily reflect a new negative view on DaVita's fundamentals, making a 'hold' recommendation appropriate for existing investors. New investors should consider broader market and company-specific fundamentals.

Keywords

Berkshire Hathaway, DaVita Inc., DVA, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Warren Buffett, Institutional Investor, Healthcare Services